ticlopidine has been researched along with Inflammation in 57 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We proposed that clopidogrel therapy in patients with stable coronary artery disease imparts a pleiotropic effect that extends beyond antiplatelet aggregation to other atheroprotective processes." | 9.19 | Effects of clopidogrel therapy on oxidative stress, inflammation, vascular function, and progenitor cells in stable coronary artery disease. ( Binongo, JN; Dhawan, SS; Ghazzal, ZB; Pohlel, FK; Quyyumi, AA; Ramadan, R; Syed, H, 2014) |
| "Aspirin reduces several pro-inflammatory markers in patients with coronary heart disease (CHD), while limited data exists with clopidogrel." | 9.12 | No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease. ( Arnesen, H; Pettersen, AA; Seljeflot, I; Solheim, S, 2006) |
| "A strategy of clopidogrel with GP IIb/IIIa blockade resulted in superior inhibition of inflammation and cardiac marker release, which was accompanied by superior platelet inhibition immediately after percutaneous coronary intervention compared with a strategy of clopidogrel alone." | 9.12 | Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study. ( Bliden, KP; Gurbel, PA; Tantry, US, 2006) |
| "A number of reports have demonstrated that obesity is a risk factor for a reduced clopidogrel pharmacodynamic response." | 8.95 | Obesity and Inflammation and Altered Clopidogrel Pharmacokinetics and Pharmacodynamics. ( Monte, SV; Norgard, NB, 2017) |
| "We measured serum levels of proinflammatory/prothrombotic markers P-selectin, CD40L, matrix metalloproteinase 9 (MMP-9), intracellular adhesion molecule 1 (ICAM-1), and interleukin (IL)-6 in ischemic stroke patients, correlating their levels with the results of aspirin (ASA) and clopidogrel antiplatelet responses, using 3 "point of care" platelet function instruments, thromboelastograph (TEG), Accumetrics (ACU), and impedance aggregometer (IMP)." | 7.83 | Relationship between Inflammation and Aspirin and Clopidogrel Antiplatelet Responses in Acute Ischemic Stroke. ( Ambrus, JL; Chichelli, T; Ching, M; Janicke, D; Munschauer, F; Sawyer, R; Sternberg, D; Sternberg, Z; Yu, J, 2016) |
| "A clopidogrel loading dose administered during stenting attenuates inflammation marker release." | 7.75 | Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting. ( Antonino, MJ; Bliden, KP; Gurbel, PA; Mahla, E; Tantry, US, 2009) |
| "This study demonstrates that clopidogrel reduces inflammation and neointimal formation in balloon-denuded iliac arteries of hypercholesterolemic rabbits." | 7.74 | Effect of clopidogrel on neointimal formation and inflammation in balloon-denuded and radiated hypercholesterolemic rabbit iliac arteries. ( Baffour, R; Chan, R; Hellinga, D; Kolodgie, F; Pakala, R; Roy, P; Scheinowitz, M; Seabron, R; Virmani, R; Waksman, R, 2008) |
| " A significant dose-response was also observed for the vasodilator-stimulated phosphoprotein index, a measure of P2Y(12) receptor inhibition." | 6.72 | A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) t ( Bal-dit-Sollier, C; Beygui, F; Collet, JP; Drouet, L; Henry, P; Lellouche, N; Meuleman, C; Milleron, O; Montalescot, G; Sideris, G; Slama, M; Steg, PG, 2006) |
| "Atherosclerosis is an inflammatory response of the arterial wall to 'injury', which is prominently driven by inflammatory factors." | 5.34 | Effect of clopidogrel on the inflammatory progression of early atherosclerosis in rabbits model. ( Li, M; Ren, H; Zhang, Y; Zhu, X, 2007) |
| " We proposed that clopidogrel therapy in patients with stable coronary artery disease imparts a pleiotropic effect that extends beyond antiplatelet aggregation to other atheroprotective processes." | 5.19 | Effects of clopidogrel therapy on oxidative stress, inflammation, vascular function, and progenitor cells in stable coronary artery disease. ( Binongo, JN; Dhawan, SS; Ghazzal, ZB; Pohlel, FK; Quyyumi, AA; Ramadan, R; Syed, H, 2014) |
| "To investigate, in the prospective CESSATION study, the effect of clopidogrel withdrawal at 1 year after DES implantation on (i) arachidonic acid (AA)- and adenosine diphosphate (ADP)-induced platelet aggregation, and (ii) biomarkers of vascular inflammation, including soluble CD40 ligand (sCD40L), high-sensitivity C-reactive protein (hsCRP) and interleukin 6 (IL-6)." | 5.15 | Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study. ( Calver, A; Corbett, S; Curzen, N; Dent, H; Englyst, N; Gray, H; Leadbeater, P; Morgan, J; Roderick, P; Sambu, N; Simpson, I; Warner, TD, 2011) |
| "This study was designed to evaluate the effects of long-term clopidogrel and aspirin administration on platelet aggregation, activation, and inflammation." | 5.13 | The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study. ( Chan, S; Madsen, EH; Maurer-Spurej, E; Saw, J, 2008) |
| " Seventeen patients with acute myocardial infarction were divided into 2 groups: (A) clopidogrel plus tirofiban infusion administered together during inclusion (n = 10); (B) clopidogrel administered at inclusion and followed 2 hours after by tirofiban (n = 7)." | 5.13 | Effects of coronary prestenting platelet inhibition on coronary poststenting inflammation. ( Azcona, L; Farré, J; Fernández-Ortiz, A; López-Farré, AJ; Macaya, C; Romero, J; Sacristán, D; Zamorano-León, JJ, 2008) |
| "Aspirin can inhibit inflammatory reactions and platelet aggregation, but little is known about the effects of the combination of aspirin plus clopidogrel, a new antiplatelet agent, on inflammation." | 5.12 | Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. ( Chen, YG; Ji, QS; Li, RJ; Lü, RJ; Sun, Y; Xu, F; Zhang, Y, 2006) |
| "Aspirin reduces several pro-inflammatory markers in patients with coronary heart disease (CHD), while limited data exists with clopidogrel." | 5.12 | No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease. ( Arnesen, H; Pettersen, AA; Seljeflot, I; Solheim, S, 2006) |
| "A strategy of clopidogrel with GP IIb/IIIa blockade resulted in superior inhibition of inflammation and cardiac marker release, which was accompanied by superior platelet inhibition immediately after percutaneous coronary intervention compared with a strategy of clopidogrel alone." | 5.12 | Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study. ( Bliden, KP; Gurbel, PA; Tantry, US, 2006) |
| "Impaired antiplatelet response to clopidogrel but not to aspirin may contribute to smaller anti-inflammatory response in patients with ST-elevation myocardial infarction." | 5.12 | Relation between impaired antiplatelet response to clopidogrel and possible pleiotropic effects. ( Bobilewicz, D; Filipiak, KJ; Grabowski, M; Huczek, Z; Imiela, T; Malek, LA; Opolski, G; Spiewak, M; Szpotanska, M, 2007) |
| "We studied 18 558 patients with ischemic stroke, myocardial infarction, or peripheral arterial disease who participated in the trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE), a study that compared the occurrence of ischemic stroke, myocardial infarction, or vascular death under randomized treatment with aspirin or clopidogrel." | 5.11 | Leukocyte count as an independent predictor of recurrent ischemic events. ( Boddy, AW; Brandt, T; Buggle, F; Dukovic, DA; Grau, AJ; Hacke, W; Lichy, C, 2004) |
| "A number of reports have demonstrated that obesity is a risk factor for a reduced clopidogrel pharmacodynamic response." | 4.95 | Obesity and Inflammation and Altered Clopidogrel Pharmacokinetics and Pharmacodynamics. ( Monte, SV; Norgard, NB, 2017) |
| "We measured serum levels of proinflammatory/prothrombotic markers P-selectin, CD40L, matrix metalloproteinase 9 (MMP-9), intracellular adhesion molecule 1 (ICAM-1), and interleukin (IL)-6 in ischemic stroke patients, correlating their levels with the results of aspirin (ASA) and clopidogrel antiplatelet responses, using 3 "point of care" platelet function instruments, thromboelastograph (TEG), Accumetrics (ACU), and impedance aggregometer (IMP)." | 3.83 | Relationship between Inflammation and Aspirin and Clopidogrel Antiplatelet Responses in Acute Ischemic Stroke. ( Ambrus, JL; Chichelli, T; Ching, M; Janicke, D; Munschauer, F; Sawyer, R; Sternberg, D; Sternberg, Z; Yu, J, 2016) |
| "Within this retrospective observational spontaneous clinical study 44 patients (31 males and 13 females) all presenting stable coronary artery disease were evaluated; 25 subjects were treated with only acetylsalicylic acid and/or clopidogrel in association with statins (standard therapeutic protocol) while for the other 18 subjects the standard therapeutic protocol was integrated with Arnica comp." | 3.83 | Effects of Arnica comp.-Heel® on reducing cardiovascular events in patients with stable coronary disease. ( Bianchi, M; Di Nardo, V; Fioranelli, M; Roccia, MG, 2016) |
| " Long-term administration of cilostazol is more effective in reducing neointimal formation at non-overlapping segments of BESs in a porcine coronary model." | 3.79 | The impact of triple anti-platelet therapy for endothelialization and inflammatory response at overlapping bioabsorbable polymer coated drug-eluting stents in a porcine coronary model. ( Ahn, Y; Cho, JG; Hong, YJ; Jeong, MH; Kang, JC; Kim, JH; Kim, JM; Kim, KH; Lee, KH; Lim, KS; Park, DS; Park, HW; Park, JC; Park, KH; Sim, DS; Yoon, HJ; Yoon, NS, 2013) |
| "A clopidogrel loading dose administered during stenting attenuates inflammation marker release." | 3.75 | Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting. ( Antonino, MJ; Bliden, KP; Gurbel, PA; Mahla, E; Tantry, US, 2009) |
| "This study demonstrates that clopidogrel reduces inflammation and neointimal formation in balloon-denuded iliac arteries of hypercholesterolemic rabbits." | 3.74 | Effect of clopidogrel on neointimal formation and inflammation in balloon-denuded and radiated hypercholesterolemic rabbit iliac arteries. ( Baffour, R; Chan, R; Hellinga, D; Kolodgie, F; Pakala, R; Roy, P; Scheinowitz, M; Seabron, R; Virmani, R; Waksman, R, 2008) |
| " A significant dose-response was also observed for the vasodilator-stimulated phosphoprotein index, a measure of P2Y(12) receptor inhibition." | 2.72 | A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) t ( Bal-dit-Sollier, C; Beygui, F; Collet, JP; Drouet, L; Henry, P; Lellouche, N; Meuleman, C; Milleron, O; Montalescot, G; Sideris, G; Slama, M; Steg, PG, 2006) |
| "As well as initiating thrombus formation at the site of a ruptured atherosclerotic plaque, platelets play a key role in vascular inflammation, through release of their own pro-inflammatory mediators and interactions with other relevant cell types (endothelial cells, leukocytes, and smooth muscle cells)." | 2.44 | Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. ( Badimon, JJ; Bhatt, DL; Herbert, JM; Lüscher, TF; Steinhubl, SR, 2007) |
| "Left ventricular thrombus (LVT) and rupture are important mechanical complications following myocardial infarction (MI) and are believed to be due to unrelated mechanisms." | 1.37 | Role of intramural platelet thrombus in the pathogenesis of wall rupture and intra-ventricular thrombosis following acute myocardial infarction. ( Dart, AM; Du, XJ; Gao, XM; Head, GA; Kiriazis, H; Liu, Y; Lobo, A; Shan, L, 2011) |
| "Clopidogrel has been used to treat atherosclerosis; however, the mechanism is not entirely known." | 1.36 | Effects of clopidogrel on vascular proliferation and apoptosis in an atherosclerotic rabbit model. ( Feng, L; Jiang, J; Li, M; Ren, H; Zhang, Y; Zhu, X, 2010) |
| "Atherosclerosis is an inflammatory response of the arterial wall to 'injury', which is prominently driven by inflammatory factors." | 1.34 | Effect of clopidogrel on the inflammatory progression of early atherosclerosis in rabbits model. ( Li, M; Ren, H; Zhang, Y; Zhu, X, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 25 (43.86) | 29.6817 |
| 2010's | 31 (54.39) | 24.3611 |
| 2020's | 1 (1.75) | 2.80 |
| Authors | Studies |
|---|---|
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Jain, N | 1 |
| Corken, A | 1 |
| Arthur, JM | 1 |
| Ware, J | 1 |
| Arulprakash, N | 1 |
| Dai, J | 1 |
| Phadnis, MA | 1 |
| Davis, O | 1 |
| Rahmatallah, Y | 1 |
| Mehta, JL | 1 |
| Hedayati, SS | 1 |
| Smyth, S | 1 |
| Kiers, D | 1 |
| van der Heijden, WA | 1 |
| van Ede, L | 1 |
| Gerretsen, J | 1 |
| de Mast, Q | 1 |
| van der Ven, AJ | 1 |
| El Messaoudi, S | 1 |
| Rongen, GA | 1 |
| Gomes, M | 1 |
| Kox, M | 1 |
| Pickkers, P | 1 |
| Riksen, NP | 1 |
| Garcia, AE | 2 |
| Rico, MC | 2 |
| Liverani, E | 1 |
| DeLa Cadena, RA | 2 |
| Bray, PF | 1 |
| Kunapuli, SP | 2 |
| Ramadan, R | 1 |
| Dhawan, SS | 1 |
| Syed, H | 1 |
| Pohlel, FK | 1 |
| Binongo, JN | 1 |
| Ghazzal, ZB | 1 |
| Quyyumi, AA | 1 |
| Kuliczkowski, W | 2 |
| Gasior, M | 2 |
| Pres, D | 2 |
| Kaczmarski, J | 2 |
| Laszowska, A | 1 |
| Szewczyk, M | 1 |
| Hawranek, M | 1 |
| Tajstra, M | 1 |
| Zeglen, S | 1 |
| Polonski, L | 2 |
| Serebruany, VL | 1 |
| Siasos, G | 1 |
| Zaromitidou, M | 1 |
| Oikonomou, E | 1 |
| Mourouzis, K | 1 |
| Tsalamandris, S | 1 |
| Kioufis, S | 1 |
| Kokkou, E | 1 |
| Vavuranakis, M | 1 |
| Zografos, T | 1 |
| Antonopoulos, A | 1 |
| Dimitropoulos, S | 1 |
| Stefanadis, C | 1 |
| Papavassiliou, AG | 1 |
| Tousoulis, D | 1 |
| Thomas, MR | 1 |
| Outteridge, SN | 1 |
| Ajjan, RA | 1 |
| Phoenix, F | 1 |
| Sangha, GK | 1 |
| Faulkner, RE | 1 |
| Ecob, R | 1 |
| Judge, HM | 1 |
| Khan, H | 1 |
| West, LE | 1 |
| Dockrell, DH | 1 |
| Sabroe, I | 1 |
| Storey, RF | 1 |
| Sternberg, Z | 1 |
| Chichelli, T | 1 |
| Sternberg, D | 1 |
| Sawyer, R | 1 |
| Ching, M | 1 |
| Janicke, D | 1 |
| Ambrus, JL | 1 |
| Yu, J | 1 |
| Munschauer, F | 1 |
| Fioranelli, M | 1 |
| Bianchi, M | 1 |
| Roccia, MG | 1 |
| Di Nardo, V | 1 |
| Layne, K | 1 |
| Di Giosia, P | 1 |
| Ferro, A | 1 |
| Passacquale, G | 1 |
| Furlong, CE | 1 |
| Marsillach, J | 1 |
| Jarvik, GP | 1 |
| Costa, LG | 1 |
| Oh, M | 1 |
| Lee, CW | 1 |
| Lee, HS | 1 |
| Chang, M | 1 |
| Ahn, JM | 1 |
| Park, DW | 1 |
| Kang, SJ | 1 |
| Lee, SW | 1 |
| Kim, YH | 1 |
| Moon, DH | 1 |
| Park, SW | 1 |
| Park, SJ | 1 |
| Milanowski, L | 1 |
| Pordzik, J | 1 |
| Janicki, PK | 1 |
| Kaplon-Cieslicka, A | 1 |
| Rosiak, M | 1 |
| Peller, M | 1 |
| Tyminska, A | 1 |
| Ozieranski, K | 1 |
| Filipiak, KJ | 2 |
| Opolski, G | 2 |
| Mirowska-Guzel, D | 1 |
| Postula, M | 1 |
| Norgard, NB | 1 |
| Monte, SV | 1 |
| Saw, J | 1 |
| Madsen, EH | 1 |
| Chan, S | 1 |
| Maurer-Spurej, E | 1 |
| Akbulut, M | 1 |
| Kutlu, M | 1 |
| Ozbay, Y | 1 |
| Polat, V | 1 |
| Bilen, MN | 1 |
| Baydas, A | 1 |
| Altas, Y | 1 |
| Antonino, MJ | 1 |
| Mahla, E | 1 |
| Bliden, KP | 2 |
| Tantry, US | 2 |
| Gurbel, PA | 2 |
| Azar, RR | 1 |
| Badaoui, G | 1 |
| Sarkis, A | 1 |
| Kassab, R | 1 |
| Salamé, E | 1 |
| Aboujaoudé, S | 1 |
| Hamdan, R | 1 |
| Barakett, V | 1 |
| Germanos, M | 1 |
| Bilodeau, ML | 1 |
| Simon, DI | 1 |
| Dosh, K | 1 |
| Berger, PB | 1 |
| Marso, S | 1 |
| van Lente, F | 1 |
| Brennan, DM | 1 |
| Charnigo, R | 1 |
| Topol, EJ | 1 |
| Steinhubl, S | 1 |
| Ren, H | 2 |
| Li, M | 2 |
| Feng, L | 1 |
| Jiang, J | 1 |
| Zhang, Y | 5 |
| Zhu, X | 2 |
| Geisler, T | 2 |
| Mueller, K | 1 |
| Aichele, S | 2 |
| Bigalke, B | 2 |
| Stellos, K | 2 |
| Htun, P | 2 |
| Ninci, E | 1 |
| Fateh-Moghadam, S | 2 |
| May, AE | 2 |
| Gawaz, M | 2 |
| Hagiwara, S | 1 |
| Iwasaka, H | 1 |
| Hasegawa, A | 1 |
| Oyama, M | 1 |
| Imatomi, R | 1 |
| Uchida, T | 1 |
| Noguchi, T | 1 |
| Müller, K | 1 |
| Herkommer, M | 1 |
| Flather, M | 1 |
| Du, XJ | 1 |
| Shan, L | 1 |
| Gao, XM | 1 |
| Kiriazis, H | 1 |
| Liu, Y | 1 |
| Lobo, A | 1 |
| Head, GA | 1 |
| Dart, AM | 1 |
| Kalantzi, KI | 1 |
| Dimitriou, AA | 1 |
| Milionis, HJ | 1 |
| Goudevenos, IA | 1 |
| Tselepis, AD | 1 |
| Greif, M | 1 |
| Sambu, N | 1 |
| Dent, H | 1 |
| Englyst, N | 1 |
| Warner, TD | 1 |
| Leadbeater, P | 1 |
| Roderick, P | 1 |
| Gray, H | 1 |
| Simpson, I | 1 |
| Corbett, S | 1 |
| Calver, A | 1 |
| Morgan, J | 1 |
| Curzen, N | 1 |
| Winning, J | 1 |
| Claus, RA | 1 |
| Pletz, MW | 1 |
| Bauer, M | 1 |
| Lösche, W | 1 |
| Rodríguez-Yáñez, M | 1 |
| Arias-Rivas, S | 1 |
| Fernández-Ferro, J | 1 |
| Leira, R | 1 |
| Castillo, J | 1 |
| Blanco, M | 1 |
| Mada, SR | 1 |
| Osmancik, P | 1 |
| Paulu, P | 1 |
| Tousek, P | 1 |
| Kocka, V | 1 |
| Widimsky, P | 1 |
| Morel, O | 1 |
| El Ghannudi, S | 1 |
| Hess, S | 1 |
| Reydel, A | 1 |
| Crimizade, U | 1 |
| Jesel, L | 1 |
| Radulescu, B | 1 |
| Wiesel, ML | 1 |
| Gachet, C | 1 |
| Ohlmann, P | 1 |
| Amison, R | 1 |
| Page, C | 1 |
| Pitchford, S | 1 |
| Liu, O | 1 |
| Jia, L | 1 |
| Liu, X | 1 |
| Wang, Y | 1 |
| Wang, X | 1 |
| Qin, Y | 1 |
| Du, J | 1 |
| Zhang, H | 1 |
| Park, KH | 1 |
| Jeong, MH | 1 |
| Kim, JM | 1 |
| Park, DS | 1 |
| Kim, JH | 2 |
| Lim, KS | 1 |
| Lee, KH | 1 |
| Sim, DS | 1 |
| Yoon, HJ | 1 |
| Yoon, NS | 1 |
| Kim, KH | 1 |
| Park, HW | 1 |
| Hong, YJ | 1 |
| Ahn, Y | 1 |
| Cho, JG | 1 |
| Park, JC | 1 |
| Kang, JC | 1 |
| Grau, AJ | 1 |
| Boddy, AW | 1 |
| Dukovic, DA | 1 |
| Buggle, F | 1 |
| Lichy, C | 1 |
| Brandt, T | 1 |
| Hacke, W | 1 |
| Furman, MI | 1 |
| Krueger, LA | 1 |
| Linden, MD | 1 |
| Fox, ML | 1 |
| Ball, SP | 1 |
| Barnard, MR | 1 |
| Frelinger, AL | 1 |
| Michelson, AD | 1 |
| Dibra, A | 1 |
| Mehilli, J | 1 |
| Braun, S | 1 |
| Hadamitzky, M | 1 |
| Baum, H | 1 |
| Dirschinger, J | 1 |
| Schühlen, H | 1 |
| Schömig, A | 1 |
| Kastrati, A | 1 |
| Lipcsey, M | 1 |
| Larsson, A | 1 |
| Olovsson, M | 1 |
| Sjölin, J | 1 |
| Eriksson, MB | 1 |
| Graff, J | 1 |
| Harder, S | 1 |
| Wahl, O | 1 |
| Scheuermann, EH | 1 |
| Gossmann, J | 1 |
| Chen, YG | 1 |
| Xu, F | 1 |
| Ji, QS | 1 |
| Sun, Y | 1 |
| Lü, RJ | 1 |
| Li, RJ | 1 |
| Angiolillo, DJ | 1 |
| Fernandez-Ortiz, A | 2 |
| Bernardo, E | 1 |
| Ramírez, C | 1 |
| Sabaté, M | 1 |
| Jimenez-Quevedo, P | 1 |
| Hernández, R | 1 |
| Moreno, R | 1 |
| Escaned, J | 1 |
| Alfonso, F | 1 |
| Bañuelos, C | 1 |
| Costa, MA | 1 |
| Bass, TA | 1 |
| Macaya, C | 2 |
| Defuentes, G | 1 |
| Lecoules, S | 1 |
| Vedrine, L | 1 |
| Coutant, G | 1 |
| Baranger, B | 1 |
| Algayres, JP | 1 |
| Davì, G | 1 |
| Santilli, F | 1 |
| Késmárky, G | 1 |
| Fehér, G | 1 |
| Koltai, K | 1 |
| Horváth, B | 1 |
| Tóth, K | 1 |
| Montalescot, G | 1 |
| Sideris, G | 1 |
| Meuleman, C | 1 |
| Bal-dit-Sollier, C | 1 |
| Lellouche, N | 1 |
| Steg, PG | 1 |
| Slama, M | 1 |
| Milleron, O | 1 |
| Collet, JP | 1 |
| Henry, P | 1 |
| Beygui, F | 1 |
| Drouet, L | 1 |
| Inoue, T | 1 |
| Hikichi, Y | 1 |
| Morooka, T | 1 |
| Yoshida, K | 1 |
| Fujimatsu, D | 1 |
| Komoda, H | 1 |
| Kameda, M | 1 |
| Nonaka, M | 1 |
| Sohma, R | 1 |
| Hashimoto, S | 1 |
| Node, K | 1 |
| Solheim, S | 1 |
| Pettersen, AA | 1 |
| Arnesen, H | 1 |
| Seljeflot, I | 1 |
| Ozdol, C | 1 |
| Gulec, S | 1 |
| Rahimov, U | 1 |
| Atmaca, Y | 1 |
| Turhan, S | 1 |
| Erol, C | 1 |
| Malek, LA | 1 |
| Grabowski, M | 1 |
| Spiewak, M | 1 |
| Szpotanska, M | 1 |
| Imiela, T | 1 |
| Huczek, Z | 1 |
| Bobilewicz, D | 1 |
| Steinhubl, SR | 1 |
| Badimon, JJ | 1 |
| Bhatt, DL | 1 |
| Herbert, JM | 1 |
| Lüscher, TF | 1 |
| Waksman, R | 1 |
| Pakala, R | 1 |
| Roy, P | 1 |
| Baffour, R | 1 |
| Hellinga, D | 1 |
| Seabron, R | 1 |
| Chan, R | 1 |
| Scheinowitz, M | 1 |
| Kolodgie, F | 1 |
| Virmani, R | 1 |
| Sacristán, D | 1 |
| López-Farré, AJ | 1 |
| Zamorano-León, JJ | 1 |
| Azcona, L | 1 |
| Romero, J | 1 |
| Farré, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin[NCT03869268] | Phase 4 | 72 participants (Actual) | Interventional | 2019-04-24 | Completed | ||
| Characterisation of a Novel Regimen of Very Low-dose Aspirin Combined With Rivaroxaban in Patients With Chronic Coronary Syndromes: WILL lOWer Dose Aspirin be Better With Rivaroxaban in Patients With Chronic Coronary Syndromes?[NCT04990791] | Phase 4 | 48 participants (Anticipated) | Interventional | 2021-08-26 | Recruiting | ||
| Phase 4 Study of Clopidogrel in Patients With Stable Coronary Artery Disease to Determine Effects on Vascular Function, Biomarkers and Endothelial Progrenitor Cells[NCT01283282] | Phase 4 | 48 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Study of the Effect of Ticagrelor and Clopidogrel on the Immune Response of Healthy Volunteers[NCT01846559] | Phase 4 | 30 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145] | Phase 4 | 40 participants (Actual) | Interventional | 2020-06-23 | Completed | ||
| Non-randomized, Open-label, Historical Control, Single Group Assignment Trial of a Reduced Dose of Unfractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions[NCT00735280] | Phase 4 | 2,505 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis.[NCT00360386] | Phase 2 | 110 participants | Interventional | 2004-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Flow-mediated dilation (FMD) collected by an ultrasound and is measured by the percent change in diameter of the brachial artery from baseline to 12 weeks. (NCT01283282)
Timeframe: Baseline, Week 12
| Intervention | percent change in diameter (Mean) |
|---|---|
| Clopridogrel | 4.89 |
| Placebo | 4.81 |
CD40 ligand levels were measured. The level of CD40 ligand were measured using the Flurokine MultiAnalyte profiling (MAP) Human Base Kit B. (NCT01283282)
Timeframe: Week 12
| Intervention | pg/mL (Mean) |
|---|---|
| Clopridogrel | 1202.21 |
| Placebo | 2169.32 |
High-sensitivity C-reactive protein (hsCRP) was measured. The hsCRP levels were measured by Dade Behring nephelometry. (NCT01283282)
Timeframe: Week 12
| Intervention | mg/L (Mean) |
|---|---|
| Clopridogrel | 5.98 |
| Placebo | 4.31 |
Nitroglycerin (NTG)-mediated vasodilation was measured after 0.4 mg of NTG was administered sublingually. Brachial artery images were obtained via ultrasound after three minutes of NTG administration. Measurements from the twelve frames will be averaged to calculate the percent change in diameter of the brachial artery from baseline to 12 weeks. (NCT01283282)
Timeframe: Baseline, Week 12
| Intervention | percent change in diameter (Mean) |
|---|---|
| Clopridogrel | 19.31 |
| Placebo | 17.10 |
PWV was measured between the carotid and femoral arteries using the SphygmoCor device. Pressure waveforms at the carotid and femoral arteries were acquired using EKG gating. Velocity (distance per time in seconds) was calculated using the foot-to-foot method and the distance between the sites was measured manually. (NCT01283282)
Timeframe: Week 12
| Intervention | m/s (Mean) |
|---|---|
| Clopridogrel | 8.77 |
| Placebo | 9.044 |
The circulating progenitor-enriched population of cells was measured by the expression of surface antigens using direct flow cytometry for CD34+, CD34+/CD133+, CD34+/ VEGF2R+ and CD34+/CD133+/VEGF2R+ (NCT01283282)
Timeframe: Week 12
| Intervention | cells/µL (Mean) | |||
|---|---|---|---|---|
| CD34+ | CD34+/133+ | CD34+/VEGF2R+ | CD34+/CD133+/VEGF2R+ | |
| Clopidogrel | 1.46 | 0.68 | 0.08 | 0.03 |
| Placebo | 1.54 | 0.75 | 0.09 | 0.03 |
Oxidative stress was measured by using liquid chromatography to collect plasma cystine, cysteine, gluthione, and oxidized glutathione levels. (NCT01283282)
Timeframe: Week 12
| Intervention | µM (Mean) | |||
|---|---|---|---|---|
| Cystine | Cysteine | Glutathione | Oxidized glutathione | |
| Clopridogrel | 105.25 | 13.71 | 1.52 | 0.08 |
| Placebo | 102.39 | 14.75 | 1.71 | 0.19 |
4 reviews available for ticlopidine and Inflammation
| Article | Year |
|---|---|
Obesity and Inflammation and Altered Clopidogrel Pharmacokinetics and Pharmacodynamics.
Topics: Cardiovascular Diseases; Clopidogrel; Humans; Inflammation; Obesity; Platelet Aggregation Inhibitors | 2017 |
[Clopidogrel and stroke].
Topics: Acute Disease; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans; Inflamm | 2011 |
Pharmacological modulation of the inflammatory actions of platelets.
Topics: Animals; Blood Platelets; Clopidogrel; Humans; Inflammation; NF-kappa B; Platelet Activation; Platel | 2012 |
Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease.
Topics: Angina, Unstable; Aspirin; Atherosclerosis; Biomarkers; Blood Platelets; Clopidogrel; Humans; Inflam | 2007 |
23 trials available for ticlopidine and Inflammation
| Article | Year |
|---|---|
Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease.
Topics: Adenosine; Clopidogrel; Female; Humans; Inflammation; Male; Middle Aged; Platelet Aggregation; Plate | 2023 |
A randomised trial on the effect of anti-platelet therapy on the systemic inflammatory response in human endotoxaemia.
Topics: Adenosine; Administration, Intravenous; Adolescent; Adult; Aspirin; Cells, Cultured; Clopidogrel; Cy | 2017 |
A randomised trial on the effect of anti-platelet therapy on the systemic inflammatory response in human endotoxaemia.
Topics: Adenosine; Administration, Intravenous; Adolescent; Adult; Aspirin; Cells, Cultured; Clopidogrel; Cy | 2017 |
A randomised trial on the effect of anti-platelet therapy on the systemic inflammatory response in human endotoxaemia.
Topics: Adenosine; Administration, Intravenous; Adolescent; Adult; Aspirin; Cells, Cultured; Clopidogrel; Cy | 2017 |
A randomised trial on the effect of anti-platelet therapy on the systemic inflammatory response in human endotoxaemia.
Topics: Adenosine; Administration, Intravenous; Adolescent; Adult; Aspirin; Cells, Cultured; Clopidogrel; Cy | 2017 |
Effects of clopidogrel therapy on oxidative stress, inflammation, vascular function, and progenitor cells in stable coronary artery disease.
Topics: Aged; Biomarkers; Blood Vessels; Capillaries; Clopidogrel; Coronary Artery Disease; Cross-Over Studi | 2014 |
Effects of CYP2C19 Polymorphism on Endothelial Function, Arterial Stiffness and Inflammation in Coronary Artery Disease Patients Under Clopidogrel Treatment.
Topics: Aged; Aged, 80 and over; Aspirin; Brachial Artery; Clopidogrel; Coronary Artery Disease; Cytochrome | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel | 2015 |
Anti-platelet drugs attenuate the expansion of circulating CD14highCD16+ monocytes under pro-inflammatory conditions.
Topics: Adult; Aspirin; Biomarkers; C-Reactive Protein; Cell Proliferation; Clopidogrel; Cytokines; Female; | 2016 |
Similar Impact of Clopidogrel or Ticagrelor on Carotid Atherosclerotic Plaque Inflammation.
Topics: Adenosine; Aged; Anti-Inflammatory Agents; Carotid Arteries; Carotid Stenosis; Clopidogrel; Female; | 2016 |
New single-nucleotide polymorphisms associated with differences in platelet reactivity and their influence on survival in patients with type 2 diabetes treated with acetylsalicylic acid: an observational study.
Topics: Aged; Alleles; Aspirin; Blood Platelets; Clopidogrel; Diabetes Mellitus, Type 2; Female; Genotype; H | 2017 |
The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Drug Therapy, Combination; Fema | 2008 |
Efficacy of clopidrogel on reperfusion and high-sensitivity C-reactive protein in patients with acute myocardial infarction.
Topics: Aspirin; C-Reactive Protein; Clopidogrel; Coronary Circulation; Creatine Kinase, MB Form; Drug Thera | 2009 |
Effect of high bolus dose tirofiban on the inflammatory response following percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Biomarkers; C-Reactive Protein; CD40 Antigens; Clopidogrel; Creatine | 2010 |
Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study.
Topics: Aged; Biomarkers; C-Reactive Protein; CD40 Ligand; Clopidogrel; Coronary Artery Disease; Coronary Ve | 2011 |
High leukocyte count and interleukin-10 predict high on-treatment-platelet-reactivity in patients treated with clopidogrel.
Topics: Age Factors; Aged; Biomarkers; CD40 Ligand; Clopidogrel; Diabetes Mellitus; Drug Resistance; Female; | 2012 |
Leukocyte count as an independent predictor of recurrent ischemic events.
Topics: Aspirin; Biomarkers; Brain Ischemia; Cause of Death; Clopidogrel; Female; Humans; Inflammation; Leuk | 2004 |
GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Topics: Abciximab; Acute Disease; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Blood Platel | 2005 |
Anti-inflammatory effects of clopidogrel intake in renal transplant patients: effects on platelet-leukocyte interactions, platelet CD40 ligand expression, and proinflammatory biomarkers.
Topics: Adult; Aged; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; C-Reactive Protein; CD11b Antige | 2005 |
Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome.
Topics: Adult; Aged; Angina, Unstable; Aspirin; C-Reactive Protein; Clopidogrel; Drug Therapy, Combination; | 2006 |
A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) t
Topics: Acute Disease; Adenosine Diphosphate; Aged; Biomarkers; Clopidogrel; Dose-Response Relationship, Dru | 2006 |
A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) t
Topics: Acute Disease; Adenosine Diphosphate; Aged; Biomarkers; Clopidogrel; Dose-Response Relationship, Dru | 2006 |
A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) t
Topics: Acute Disease; Adenosine Diphosphate; Aged; Biomarkers; Clopidogrel; Dose-Response Relationship, Dru | 2006 |
A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) t
Topics: Acute Disease; Adenosine Diphosphate; Aged; Biomarkers; Clopidogrel; Dose-Response Relationship, Dru | 2006 |
No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease.
Topics: Aspirin; Biomarkers; Chemokine CCL2; Clopidogrel; Coronary Disease; Humans; Inflammation; Ticlopidin | 2006 |
Naproxen treatment prevents periprocedural inflammatory response but not myocardial injury after percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; C-Reactive P | 2007 |
Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study.
Topics: Aged; Biomarkers; Blood Platelets; C-Reactive Protein; Clopidogrel; Creatine Kinase, MB Form; Eptifi | 2006 |
Relation between impaired antiplatelet response to clopidogrel and possible pleiotropic effects.
Topics: Aged; Aspirin; Blood Platelets; C-Reactive Protein; Clopidogrel; Drug Resistance; Female; Humans; In | 2007 |
Effects of coronary prestenting platelet inhibition on coronary poststenting inflammation.
Topics: Aged; alpha 1-Antitrypsin; Clopidogrel; Drug Administration Schedule; Female; Humans; Inflammation; | 2008 |
30 other studies available for ticlopidine and Inflammation
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
Erosive arthritis and hepatic granuloma formation induced by peptidoglycan polysaccharide in rats is aggravated by prasugrel treatment.
Topics: Animals; Arthritis, Experimental; Clopidogrel; Cytokines; Female; Granuloma; Inflammation; Joints; L | 2013 |
Aspirin 'resistance': impact on no-reflow, platelet and inflammatory biomarkers in diabetics after ST-segment elevation myocardial infarction.
Topics: Aged; Aspirin; Biomarkers; Clopidogrel; Diabetes Complications; Drug Resistance; Female; Humans; Inf | 2015 |
Relationship between Inflammation and Aspirin and Clopidogrel Antiplatelet Responses in Acute Ischemic Stroke.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Brain Ischemia; CD40 Ligand; Clopidogrel; Femal | 2016 |
Effects of Arnica comp.-Heel® on reducing cardiovascular events in patients with stable coronary disease.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Aspirin; Clopidogrel; Coronary Artery Disease; Dr | 2016 |
Paraoxonases-1, -2 and -3: What are their functions?
Topics: Animals; Aryldialkylphosphatase; Astrocytes; Carotid Artery Diseases; Cells, Cultured; Clopidogrel; | 2016 |
Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Apyrase; Blood Platelets; Clopidogrel; Female; Flow Cytometry; | 2009 |
Clopidogrel for the hot patient.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; C-Reactive Protein; Clopidogrel; Drug Therapy, | 2009 |
Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; C-Reactive Protein; Clopidogrel; Double-B | 2009 |
Effects of clopidogrel on vascular proliferation and apoptosis in an atherosclerotic rabbit model.
Topics: Animals; Apoptosis; Atherosclerosis; Atorvastatin; C-Reactive Protein; Catheterization; Clopidogrel; | 2010 |
Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Glucose; C-Reactive Protein; Clopid | 2010 |
Adenosine diphosphate receptor antagonist clopidogrel sulfate attenuates LPS-induced systemic inflammation in a rat model.
Topics: Animals; Blotting, Western; Clopidogrel; HMGB1 Protein; Inflammation; Interleukin-6; Lipopolysacchar | 2011 |
Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon; Aspirin; Blood Platelets; C-Reactive Protein; C | 2010 |
Role of intramural platelet thrombus in the pathogenesis of wall rupture and intra-ventricular thrombosis following acute myocardial infarction.
Topics: Animals; Aspirin; Blood Platelets; Clopidogrel; Disease Models, Animal; Hemodynamics; Inflammation; | 2011 |
Clopidogrel differentially affects platelet-mediated thrombosis and inflammatory response in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Female; Humans; Inflammation; Male; Mid | 2011 |
Effects of platelet and inflammatory system activation on outcomes in diabetic patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Diabetes Complicati | 2011 |
Adenosine diphosphate receptor antagonist clopidogrel sulfate attenuates LPS-induced systemic inflammation in a rat model.
Topics: Animals; Clopidogrel; Humans; Inflammation; Interleukin-6; Lipopolysaccharides; Platelet Aggregation | 2011 |
Clopidogrel, a P2Y12 receptor antagonist, potentiates the inflammatory response in a rat model of peptidoglycan polysaccharide-induced arthritis.
Topics: Animals; Arthritis, Experimental; Clopidogrel; Cytokines; Disease Models, Animal; Drug Synergism; Fe | 2011 |
The extent of P2Y12 inhibition by clopidogrel in diabetes mellitus patients with acute coronary syndrome is not related to glycaemic control: roles of white blood cell count and body weight.
Topics: Acute Coronary Syndrome; Aged; Body Weight; Clopidogrel; Diabetes Complications; Diabetes Mellitus; | 2012 |
Clopidogrel, a platelet P2Y12 receptor inhibitor, reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression.
Topics: Angiotensin II; Animals; Aortic Aneurysm, Abdominal; Apolipoproteins E; Blood Platelets; Blood Press | 2012 |
The impact of triple anti-platelet therapy for endothelialization and inflammatory response at overlapping bioabsorbable polymer coated drug-eluting stents in a porcine coronary model.
Topics: Absorbable Implants; Animals; Aspirin; Cilostazol; Clopidogrel; Coated Materials, Biocompatible; Cor | 2013 |
Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting.
Topics: Abciximab; Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Mono | 2005 |
Early endotoxin-mediated haemostatic and inflammatory responses in the clopidogrel-treated pig.
Topics: Animals; Blood Platelets; Blood Pressure; Clopidogrel; Creatinine; Endotoxins; Female; Hemostasis; H | 2005 |
Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Fema | 2006 |
[Accelerated atheroma with prednisone and clopidogrel].
Topics: Aged; Atherosclerosis; Carotid Stenosis; Clopidogrel; Endarterectomy; Giant Cell Arteritis; Glucocor | 2006 |
Unveiling the inflammatory face of antiplatelet drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Di | 2006 |
Viscosity, hemostasis and inflammation in atherosclerotic heart diseases.
Topics: Aged; Aspirin; Blood Viscosity; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Diabetes Compl | 2006 |
Comparison of changes in circulating platelet-derived microparticles and platelet surface P-selectin expression after coronary stent implantation.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angina, Unstable; Blood Platelets; Cell Membrane; Cor | 2006 |
Effect of clopidogrel on the inflammatory progression of early atherosclerosis in rabbits model.
Topics: Animals; Aspirin; Atherosclerosis; Atorvastatin; Chemokine CCL2; Clopidogrel; Diet, Atherogenic; Dis | 2007 |
Effect of clopidogrel on neointimal formation and inflammation in balloon-denuded and radiated hypercholesterolemic rabbit iliac arteries.
Topics: Angioplasty, Balloon, Coronary; Animals; C-Reactive Protein; Clopidogrel; Endothelium, Vascular; Hyp | 2008 |